Ignite Creation Date:
2024-05-06 @ 8:20 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06340360
Status:
RECRUITING
Last Update Posted:
2024-06-12
First Post:
2024-03-25
Brief Title:
A Phase 2b Study to Evaluate Rezpegaldesleukin Rezpeg in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients Rezolve AA
Sponsor:
Nektar Therapeutics
Organization:
Nektar Therapeutics
Study Overview
Official Title:
A Phase 2b Randomized Double-Blind Parallel Group Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients Rezolve AA
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an interventional randomized double blind parallel group placebo-controlled Phase 2b 3-arm study to assess the effect of pegylated-recombinant-human interleukin-2 rezpegaldesleukin in adult participants with severe to very severe alopecia areata
The estimated duration includes a screening period of up to 35 days a 36-week treatment period an optional 16-week treatment extension period and a 24-week follow-up period The maximum study duration is approximately 81 weeks for all participants
The estimated duration includes a screening period of up to 35 days a 36-week treatment period an optional 16-week treatment extension period and a 24-week follow-up period The maximum study duration is approximately 81 weeks for all participants
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2023-509981-39 | EUDRACT_NUMBER | None | None |